AK106-001616, a Potent and Selective Inhibitor of Cytosolic Phospholipase A₂: In Vivo Efficacy for Inflammation, Neuropathic Pain, and Pulmonary Fibrosis

Hiroto Shimizu, Akitoshi Ito, Katsuhiko Sakurada, Junji Nakamura, Kosuke Tanaka, Masakazu Komatsu, Mineko Takeda, Kenichi Saito, Yukiko Endo, Tomohito Kozaki, Motoshi Shoda, and Hiroshi Kuriyama

Laboratories for Pharmacology (H.S., A.I., Ka.S., J.N., K.T., M.K., M.T., Ke.S., Y.E., H.K.), Safety Assessment and ADME (T.K.), and Medicinal Chemistry (M.S.), Pharmaceuticals Research Center, Asahi Kasei Pharma Co. Ltd., Izunokuni, Shizuoka, Japan

Received December 5, 2018; accepted April 8, 2019

ABSTRACT

3-[3-Amino-4-(indan-2-yloxy)-5-(1-methyl-1*H*-indazol-5-yl)-phenyl]-propionic acid (AK106-001616) is a novel, potent, and selective inhibitor of the cytosolic phospholipase A₂ (cPLA₂) enzyme. Unlike traditional nonsteroidal anti-inflammatory drugs and selective cyclooxygenase-2 inhibitors, AK106-001616 reduced prostaglandin E₂ (PGE₂) and leukotriene B₄ (LTB₄) production by stimulated cells. The suppression of PGE₂ and LTB₄ production was also confirmed using an air pouch model in rats administered a single oral dose of AK106-001616. AK106-001616 alleviated paw swelling in a rat adjuvant-induced arthritis (AIA) model. The maximum effect of the inhibitory effect of AK106-001616 was comparable with that of naproxen on paw swelling in a rat AIA model. Meanwhile, the inhibitory effect of AK106-001616 was more effective than that of naproxen in the mouse collagen antibody-induced arthritis model with leukotrienes contributing

to the pathogenesis. AK106-001616 dose dependently reversed the decrease in paw withdrawal threshold not only in rat carrageenan-induced hyperalgesia, but also in a rat neuropathic pain model induced by sciatic nerve chronic constriction injury (CCI). However, naproxen and celecoxib did not reverse the decrease in the paw withdrawal threshold in the CCI model. Furthermore, AK106-001616 reduced the disease score of bleomycin-induced lung fibrosis in rats. In addition, AK106-001616 did not enhance aspirin-induced gastric damage in fasted rats, increase blood pressure, or increase the thromboxane A₂/prostaglandin I₂ ratio that is thought to be an underlying mechanism of thrombotic cardiovascular events increased by selective cyclooxygenase-2 inhibitors. Taken together, these data demonstrate that oral AK106-001616 may provide valuable effects for wide indications without attendant gastrointestinal and cardiovascular risks.

Introduction

Phospholipase A₂ (PLA₂) enzymes recognize the sn-2 acyl bond of glycerophospholipids and hydrolyze the bond. The cytosolic PLA₂ (cPLA₂) enzyme is activated by various inflammatory stimuli and preferentially cleaves arachidonic acid (AA) from membrane phospholipid (Kudo and Murakami, 2002; Ghosh et al., 2006). AA is then converted into prostaglandins (PGs) and thromboxanes by cyclooxygenase (COX) and leukotrienes (LTs) by lipoxygenase (LOX). Consequently, an inhibitor of cPLA₂ enzyme would be expected to inhibit the production of both PGs and LTs.

Nonsteroidal anti-inflammatory drugs (NSAIDs), which act as both COX-1 and COX-2 inhibitors, are widely prescribed for the relief of the signs and symptoms of rheumatoid arthritis (RA) (Combe et al., 2007) and osteoarthritis (OA) (Hochberg et al., 2012). While the use of traditional NSAIDs (tNSAIDs) is limited due to gastrointestinal (GI) toxicities, the new-generation NSAID COX-2 inhibitors have an improved GI safety profile. However, increases in thrombotic cardiovascular (CV) events have been reported in several clinical studies of COX-2 inhibitors (Bresalier et al., 2005; Nussmeier et al., 2005; Solomon et al., 2005). In addition, many meta-analyses have shown that tNSAIDs also increase the risk of thrombotic CV events (Farkouh and Greenberg, 2009; Trelle et al., 2011). Thus, CV risk needs to be taken into account when prescribing tNSAIDs and COX-2 inhibitors (Trelle et al., 2011).

This work was funded by Asahi Kasei Pharma.
All authors are or were formerly employees of Asahi Kasei Pharma.
<https://doi.org/10.1124/jpet.118.255034>.

ABBREVIATIONS: AA, arachidonic acid; AIA, adjuvant-induced arthritis; AK106-001616, 3-[3-amino-4-(indan-2-yloxy)-5-(1-methyl-1*H*-indazol-5-yl)-phenyl]-propionic acid; A23187, 5-(methylamino)-2-[[[2*S*,3*R*,5*R*,8*S*,9*S*]-3,5,9-trimethyl-2-[1-oxo-1-(1*H*-pyrrol-2-yl)propan-2-yl]-1,7-dioxaspiro[5.5]undecan-8-yl]methyl]-1,3-benzoxazole-4-carboxylic acid; CAIA, collagen antibody-induced arthritis; CCI, chronic constriction injury; COX, cyclooxygenase; cPLA₂, cytosolic phospholipase A₂; CV, cardiovascular; GI, gastrointestinal; IPF, idiopathic pulmonary fibrosis; iPLA_{2β}, independent phospholipase A_{2β}; LOX, lipoxygenase; LPS, lipopolysaccharide; LT, leukotriene; LTB₄, leukotriene B₄; LTE₄, leukotriene E₄; MC, methyl cellulose; NSAID, nonsteroidal anti-inflammatory drug; OA, osteoarthritis; PAF, platelet-activating factor; PBMC, peripheral blood mononuclear cell; PG, prostaglandin; PGE₂, prostaglandin E₂; PGEM, prostaglandin E metabolite; PGF_{1α}, prostaglandin F_{1α}; PGI₂, prostaglandin I₂; PLA₂, phospholipase A₂; RA, rheumatoid arthritis; RBL-2H3, rat basophilic leukemia 2H3; SD, Sprague-Dawley; sPLA₂, secretory phospholipase A₂; tNSAID, traditional nonsteroidal anti-inflammatory drug; TXA₂, thromboxane A₂; TXB₂, thromboxane B₂.

At present, there is no clear difference in efficacy between tNSAIDs and COX-2 inhibitors in OA patients (National Clinical Guideline Centre, 2014). Considering each side effect, use of oral tNSAIDs/COX-2 inhibitors at the lowest effective dose for the shortest possible period of time is recommended in OA patients (National Clinical Guideline Centre, 2014). The use of tNSAIDs/COX-2 inhibitors has a small benefit in relieving symptoms for patients with RA (Allen et al., 2018). For these reasons there has been focused research into alternative targets that improve the efficacy and safety of anti-inflammatory drugs.

It has been suggested that LTs, which are another group of mediators derived from cPLA₂-released AA, play critical roles in the pain and inflammation of several animal arthritis models (Jain et al., 2001; Anderson et al., 2009; Cortes-Burgos et al., 2009; Yoo et al., 2009; Masferrer et al., 2010). Since both PGs and LTs have been found to play important roles in the pathology of RA (Prete and Gurakar-Osborne, 1997; Mathis et al., 2007) and OA (Laufer, 2003), cPLA₂, which controls these mediators, could be a potent therapeutic target in RA and OA. The importance of cPLA₂ activity in the pathology of arthritis has been suggested in animal studies using cPLA₂-deficient mice (Hegen et al., 2003), antisense oligonucleotides against cPLA₂ (Raichel et al., 2008) and a specific inhibitor of cPLA₂ (Tai et al., 2010).

Neuropathic pain results from diseases or trauma affecting the nervous system, and is generally resistant to NSAIDs; it is treated with coanalgesics, antidepressants, anticonvulsant drugs, and topical agents. A large-scale meta-analysis indicates that the number needed to treat for a 50% reduction of pain by first-line drugs, antidepressants, and anticonvulsants is 3.5–7.7 (Binder and Baron, 2016). However, considering the value of the number needed to treat, the treatment success rate could be improved. Nerve damage has been shown to alter the neurophysiological properties in the peripheral and central neurons, which leads to neuronal hyperexcitability. The peripheral or central hyperexcitability can be modulated with first-line drugs, resulting in relief from pain (Binder and Baron, 2016). Since activation of cPLA₂ in dorsal root ganglion neurons (Tsuda et al., 2007) and the spinal cord (Sung et al., 2007) is involved in the pathogenesis of neuronal hyperexcitability, cPLA₂ in both the peripheral nerve and spinal cord could be a potent therapeutic target in neuropathic pain.

Pulmonary fibrosis is an interstitial disorder of the lung parenchyma. Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal form of the disorder characterized by inflammation, fibroblast proliferation, and collagen deposition (Nagase et al., 2002). In 2014, pirfenidone and nintedanib were approved for the treatment of IPF. Although both drugs reduced the progression of IPF and offered survival benefits, no pharmacologic intervention is strongly recommended for patients with IPF (Raghu et al., 2015). The high mortality rate clearly demonstrates the need to develop efficient therapeutic strategies for IPF (Liu et al., 2017). In cPLA₂-deficient mice, bleomycin-induced overproduction of thromboxanes and LTs in the lung was reduced, and attenuation of fibrosis was observed (Nagase et al., 2002).

With these observations in mind, we embarked on a medicinal chemistry-directed search and discovered 3-[3-amino-4-(indan-2-yloxy)-5-(1-methyl-1*H*-indazol-5-yl)-phenyl]-propionic acid (AK106-001616) (Fig. 1), a novel selective cPLA₂ inhibitor. The preclinical pharmacology of AK106-001616 is described subsequently.

Fig. 1. Chemical structure of AK106-001616.

Materials and Methods

Chemicals

AK106-001616 was synthesized by Asahi Kasei Pharma Co., Ltd. Zileuton and celecoxib were purchased from Toronto Research Chemicals Inc. (Toronto, Canada). Naproxen was purchased from Sigma-Aldrich (St. Louis, MO). Nintedanib was purchased from Shanghai Haoyuan Chemexpress (Shanghai, P.R. China). Rofecoxib was purchased from Kempotec (Cumbria, UK). Bleomycin was purchased from Nippon Kayaku (Tokyo, Japan). Aspirin was purchased from Cayman Chemical (Ann Arbor, MI).

Animals

Male Sprague-Dawley (SD) rats and female LEW/CrlCrJ rats were purchased from Charles River Laboratories Japan, Inc. (Yokohama, Japan). Female BALB/c and C57BL/6J mice, female and male SD/slcr rats, and male and female WKY/Hos rats were purchased from Japan SLC, Inc. (Shizuoka, Japan). Animal species, strains, and sexes used in each animal model were selected by validation with reference to previous reports. The animals were housed in a room in which the temperature and humidity were controlled to 20–26°C and 30%–70%, respectively, with a 12-hour light-dark cycle and free access to food and water.

All animal experiments were approved by the Institutional Animal Care Committee of the Pharmaceutical Research Center of Asahi Kasei Pharma Corporation, and the experimental procedures were conducted in accordance with the Guiding Principles for the Care and Use of Animals recommended by the Physiologic Society of Japan (<https://www.nips.ac.jp/faops2019/assets/dl/Guiding-principles.pdf>).

In Vitro Enzyme Studies

Human cPLA_{2α}. With reference to the previous report (Sharp et al., 1991), the gene of human cPLA_{2α} was cloned from cDNA of human spleen. This recombinant protein was produced using the expression system combining baculovirus and Sf9 cells (de Carvalho et al., 1993). The activity of human cPLA_{2α} was measured with reference to previous reports (Tojo et al., 1993; Leslie and Gelb, 2004). Using phosphatidylcholine containing AA at the second position as a substrate, the AA concentration produced by human cPLA_{2α} was quantified 60 minutes after the start of the reaction. Quantitation was carried out using high-performance liquid chromatography after fluorescence labeling of AA with 9-anthryldiazomethane (FK-101; Funakoshi, Tokyo, Japan).

Rat cPLA_{2α}. With reference to the previous report (Owada et al., 1994), the gene of rat cPLA_{2α} was cloned from cDNA of rat brain. This recombinant protein was produced using the expression system combining baculovirus and Sf9 cells (de Carvalho et al., 1993). The activity of rat cPLA_{2α} was measured with reference to previous reports (Tojo et al., 1993; Leslie and Gelb, 2004). The AA concentration produced by rat cPLA_{2α} was quantified in the same way as for human cPLA_{2α}.

Human Independent PLA_{2β}. With reference to the previous report (Larsson et al., 1998), the gene of human Ca²⁺ independent PLA_{2β} (iPLA_{2β}) was cloned from cDNA of human testis. This recombinant protein was produced using the expression system combining

baculovirus and Sf9 cells (Wolf and Gross, 1996). The activity of human iPLA_{2β} was measured with reference to previous reports (Tojo et al., 1993; Jenkins et al., 2002). Using phosphatidylcholine as a substrate, the AA concentration produced by human iPLA_{2β} was quantified 6 minutes after the start of the reaction. Quantitation was carried out using high-performance liquid chromatography after fluorescence labeling of AA with 9-anthryldiazomethane.

Bovine Secretory PLA₂ Type IB. Bovine secretory PLA₂ (sPLA₂) type IB was a commercially available product (Sigma-Aldrich). PLA₂ activity of bovine sPLA₂ IB was measured using the sPLA₂ Assay Kit (Cayman Chemical).

Platelet-Activating Factor/Acetylhydrolase. Platelet-activating factor (PAF)-inactivating enzyme PAF-acetylhydrolase (also known as type VII PLA₂) is an enzyme that inactivates PAF, an inflammatory mediator (Stafforini et al., 1987). The inhibitory effect on PAF-acetylhydrolase was examined using the PAF Acetylhydrolase Inhibitor Screening Assay Kit (Cayman Chemical).

Cellular Studies

AA Release from Rat Basophilic Leukemia 2H3 Cells. AA released from a rat basophilic leukemia 2H3 (RBL-2H3) mast cell line was measured, as previously described with slight modifications (Glover et al., 1995). Tritium-labeled AA (PerkinElmer) was incorporated into cell membrane phospholipids of RBL-2H3 cells (CRL-2256; American Type Culture Collection) by coculturing overnight. Labeled AA was released by stimulating the cells with Ca²⁺ ionophore 5-(methylamino)-2-[[[(2S,3R,5R,8S,9S)-3,5,9-trimethyl-2-[1-oxo-1-(1H-pyrrol-2-yl)propan-2-yl]-1,7-dioxaspiro[5.5]undecan-8-yl]methyl]-1,3-benzoxazole-4-carboxylic acid (A23187) (Sigma-Aldrich) at a final concentration of 0.2 μmol/l. Radioactivity of the culture supernatant was measured with a liquid scintillation counter (TRI-CARB 2300 TR; PerkinElmer Japan Co., Ltd.) 30 minutes after the stimulation by A23187. AK106-001616 was added 3 hours before stimulation by A23187 to examine its inhibitory effect on AA release.

Leukotriene B₄ Production by RBL-2H3 Cells. The production of leukotriene B₄ (LTB₄) by RBL-2H3 cells was measured as previously described with slight modifications (Hagmann, 1994; Yamashita et al., 2000). RBL-2H3 cells were stimulated with A23187 (0.4 μmol/l) in a culture solution containing AK106-001616 for 20 minutes, and the concentration of LTB₄ in the culture supernatant was measured using the Leukotriene B₄ EIA Kit (Cayman Chemical).

Prostaglandin E₂ Production by Human Peripheral Blood Mononuclear Cells. Prostaglandin E₂ (PGE₂) production by human peripheral blood mononuclear cells (PBMCs) was examined by modifying the method of a previous report (Wakitani et al., 1998). After approval of the Research Ethics Committee of Asahi Kasei Pharma Corporation and obtaining the consent of the volunteers, blood was collected from three healthy adults (because the volunteers were anonymous, the gender of each adult was unknown), and human PBMCs were prepared from the blood using Mono-Poly Resolving Medium (Sumitomo Dainippon Pharma). One hour after adding AK106-001616 to the PBMCs, 50 μl/well of lipopolysaccharide (LPS) (L4516; Sigma-Aldrich) solution (0.4 μg/ml) was added, with stimulation for 24 hours. The concentration of PGE₂ produced in the culture supernatant was measured using the Prostaglandin E₂ EIA Kit-Monoclonal (Cayman Chemical).

In Vivo Studies

Air Pouch Model in Rats. The air pouch model was created, as previously described with slight modifications (Payá et al., 1996, 1997). At the back of a 7-week-old female LEW/Cr1Cr1j rat, filter-sterilized air was injected twice at intervals of 2 days to form an egg-shaped air pouch. Drugs or 1% w/v aqueous methyl cellulose (MC) (vehicle) was administered orally once on day 6 after the first air injection, and 1 hour later a suspension of zymosan (Sigma-Aldrich) was injected into the air pouch. The dose of celecoxib was 1 mg/kg,

which sufficiently suppressed the production of PGE₂ in the preliminary test. The dose of zileuton was 5 mg/kg, which sufficiently suppressed the production of LTB₄ in the preliminary test. The exudate in the air pouch was collected 3 hours after zymosan injection. PGE₂ and LTB₄ concentrations in the exudate were measured using the Prostaglandin E₂ EIA Kit-Monoclonal and Leukotriene B₄ EIA Kit, respectively.

Rat Adjuvant-Induced Arthritis Model. The adjuvant-induced arthritis (AIA) model was prepared by slightly modifying the method described previously (Tanahashi et al., 1998). Killed Mycobacterium tuberculosis H37Ra organisms (DIFCO Laboratories, Detroit, MI) were suspended at 10 mg/ml in liquid paraffin. Female LEW/Cr1Cr1j rats were injected with 50 μl of the suspension (0.5 mg/paw) in the left hind footpad under anesthesia. Drug or 1% w/v aqueous MC (vehicle) was administered orally once a day from day 13 to 34 after adjuvant injection. The dose of naproxen was within the range where dose response was observed in the preliminary test using the AIA model. Zileuton was administered at 30 mg/kg, which is an excessive dose that suppresses the production of LTB₄ in the air pouch model. The swelling volume of the contralateral foot pad was measured as an immune response to self-antigens using a 7140 Plethysmometer (Ugo Basile S.R.L., Varese, Italy) at day 34. After randomizing the order of animals by another person different from the evaluator, measurement was carried out by masking the information about the groups from the evaluator.

To confirm the suppression of LT production by zileuton, another experiment using the AIA model was conducted and urine was collected from day 17 to 18. Urinary leukotriene E₄ (LTE₄), which is an indicator of systemic production of LT concentration, was measured using the Leukotriene E₄ EIA Kit (Cayman Chemical). Urinary PG E metabolite (PGEM), which is an indicator of systemic production of PG concentration, was measured using the Prostaglandin E Metabolite EIA Kit (Cayman Chemical). Urinary creatinine levels were determined by CRE-EN Kainos (Kainos Laboratories, Inc., Tokyo).

Mouse Collagen Antibody-Induced Arthritis Model. The collagen antibody-induced arthritis (CAIA) model was created, as previously described with some modifications (Hutamekalin et al., 2009). Female BALB/c mice received an anti-type II collagen antibody cocktail (Chondrex, Inc., Redmond, WA) (1.5 mg/head) in the tail vein on day 0 and LPS (Wako) (25 μg/head) intraperitoneally on day 3. Drug or 1% w/v aqueous MC (vehicle) was orally administered from day 0 to 12 twice a day. The dose of zileuton was 30 mg/kg, which can be expected to have sufficient effect in the preliminary test using the CAIA model. The dose of naproxen was 30 mg/kg, in which sufficient effect was observed in the AIA model. The degree of swelling of the four limbs was scored cumulatively on day 10 in the blinded manner previously described.

To confirm the suppression of LT production by zileuton, another experiment using the CAIA model was conducted and urine was collected from day 3 to 4 and day 8 to 9. Urinary LTE₄ concentration from day 3 to 4 and PGEM concentration from day 8 to 9 were measured using the Leukotriene E₄ EIA Kit and the Prostaglandin E Metabolite EIA Kit, respectively. Urinary creatinine levels were determined by CRE-EN Kainos.

Rat Carrageenan Model: In Vivo Model of Inflammatory Pain. A rat carrageenan model, which is known as an inflammatory pain model, was used (Yoshino et al., 2005). Male SD rats received 100 μl of 1% carrageenan (Sigma-Aldrich) into the hind paw. Drug or 1% w/v aqueous MC (vehicle) was dosed 1 hour before carrageenan injection. The dose of naproxen was within the range where dose response was observed in the preliminary test. Celecoxib was administered at 3 mg/kg, in which sufficient effect was observed in the preliminary test. Measurement of the hind paw withdrawal thresholds was performed in the blinded manner previously described with a 37215 Analgesy-Meter (Ugo Basile) 4 hours after carrageenan injection.

Rat Chronic Constriction Injury Model: In Vivo Model of Neuropathic Pain. The chronic constriction injury (CCI) model rats were made according to the method described previously (Ito et al., 2012). Briefly, male SD rats (7 weeks old) received four loose ligatures

placed on the sciatic nerve with 4-0 suture silk thread (Nicho Industry Co. Ltd., Tokyo, Japan) under isoflurane anesthesia on day 0. In sham-operated rats, the sciatic nerve was exposed without ligation. Drug or 1% w/v aqueous MC (vehicle) was administered orally once daily for 7 days from day 8. The doses of celecoxib and naproxen were selected within the range that efficacy was observed in the carrageenan model and tolerated by repeated administration. Measurement of the paw withdrawal threshold was performed in the blinded manner previously described with an analgesy-meter 2 hours after dosing (day 14).

Mouse Pulmonary Fibrosis Model Induced by Bleomycin Administration. A mouse bleomycin-induced pulmonary fibrosis model (Nagase et al., 2002) was modified and used. Female C57BL/6J mice were anesthetized with pentobarbital and given a single intratracheal administration of 60 μ g of bleomycin (Nippon Kayaku). Bleomycin was dissolved in physiologic saline and administered in a volume of 50 μ L. Control animals were treated with saline instead of bleomycin in the same manner. These procedures were performed in a sterile environment. Drug or 1% w/v aqueous MC (vehicle) was administered orally once daily for 14 days from day 7 after bleomycin injection. For nintedanib, a dose was selected in which sufficient effect was observed in the preliminary test. Mice were decapitated on day 21, their lungs were fixed with formalin, and Mattson-Trichrome-stained slices were prepared. According to the method of Ashcroft et al. (1988), the degree of fibrosis was scored for 20 visual fields. The average value was taken as the Ashcroft score of the individual. Evaluation of fibrosis was carried out by masking the information about the slices from the evaluator.

Side-Effect Profiling

Effects of Single Dosing on Aspirin-Induced Gastric Damage in Rats. A rat aspirin-induced gastric mucosal injury model, which is known to enhance the injury produced by a COX-2 inhibitor, was used (Fiorucci et al., 2003). The doses of celecoxib and aspirin were determined based on the results of preliminary tests with reference to the previous study (Fiorucci et al., 2003). A mixture of aspirin (70 mg/kg) and either AK106-001616 (70 or 200 mg/kg) or celecoxib (70 mg/kg) was administered as a single oral dose to male SD rats (12 rats/group) that had been fasted for approximately 24 hours to assess the effects on aspirin-induced gastric damage, namely, macroscopic depression and bleeding of the gastric mucosa, which was quantitatively indicated as a gastric lesion score (sum of the lengths of damage of the mucosa). The scoring was carried out in the blinded manner described previously.

Effects of Repeated Dosing on Blood Pressure in Rats. The systolic blood pressure was measured as previously described with slight modifications (Höcherl et al., 2002). Rofecoxib was used as a control drug because its blood pressure lowering effect was reported in the previous study (Höcherl et al., 2002). For rofecoxib, a dose was selected in which decrease of blood pressure was observed in the preliminary test. Drug or 1% w/v aqueous MC (vehicle) was repeatedly administered orally once a day for 28 days to male WKY/Hos rats (10 rats/group) by gavage to assess the effects on systolic blood

pressure measured under conscious conditions using a noninvasive blood pressure monitor (model MK-2000; Muromachi Kikai Co. Ltd., Tokyo, Japan). Measurement of blood pressure was carried out in the blinded manner described previously.

Effects on LPS-Induced Production of Thromboxane A₂ and Prostaglandin I₂ in the Rat. The concentrations of plasma prostaglandin I₂ (PGI₂) and thromboxane A₂ (TXA₂) were assessed as previously described with slight modifications (Baba, 1988). The dose range of rofecoxib was defined as the range including the dose that lowered blood pressure. Drug or 1% w/v aqueous MC (vehicle) was orally administered to female SD rats (six rats per group) 1 hour before intravenous LPS injection (B5; Sigma-Aldrich) to assess the effects on the systemic production of TXA₂ and PGI₂. Plasma levels of thromboxane B₂ (TXB₂), a stable metabolite of TXA₂, and 6-keto prostaglandin F_{1 α} (PGF_{1 α}), a stable metabolite of PGI₂, were measured as indicators of TXA₂ and PGI₂, respectively, 1 hour after LPS injection using the TXB₂ EIA Kit (Cayman Chemical) and the 6-k PGF_{1 α} EIA Kit (Cayman Chemical).

Plasma and Cerebrospinal Fluid Concentration Levels

AK106-001616 or other compounds were administered orally to the AIA model rat on day 34 after measurement of the swelling volume of the foot pad was completed. After an additional dosing of AK106-001616 or other compounds, plasma samples were collected predosing and at the following time intervals: 0.5, 1, 2, 4, 8, 12, and 24 hours postdose.

AK106-001616 or other compounds were administered orally to the CAIA model mouse on day 13. Compounds were still administered orally to the CAIA model mouse twice a day until day 12 after evaluation of the degree of swelling of the limbs was completed, and then compounds were administered again for collection of blood samples on day 13. After an additional dosing of AK106-001616 or other compounds, plasma samples were collected predosing and at the following time intervals: 0.5, 1, 2, 4, 6, 8, and 24 hours postdose.

AK106-001616 was administered orally to the CCI model rat on day 15 after measurement of paw withdrawal threshold was completed. After an additional dosing of AK106-001616, plasma samples were collected predosing and at the following time intervals: 1, 2, 4, 6, 8, and 24 hours postdose.

AK106-001616 concentrations were determined using liquid chromatography–tandem mass spectrometry analysis. Free plasma concentrations of AK106-001616 were calculated using the unbound ratio in rat or mouse plasma, 1.4% or 1.8%, respectively (unpublished in-house data). Pharmacokinetic parameters were calculated by non-compartmental analysis using Phoenix WinNonlin (Certara).

Statistical Analysis

All in vivo tests were performed prospective and confirmatory with reference to the method based on the interim analysis of the clinical trial (Maïofiss-Dullin et al., 2007). Therefore, based on the results of the preliminary tests, the criteria for establishing the test, the endpoint of

Fig. 2. Inhibitory effects of AK106-001616 on the enzyme activity of human (A) and rat (B) recombinant cPLA₂ α . Data are presented as mean $\pm$ S.D. ($n = 3$). The AA concentrations in the absence of AK106-001616, 10.2 μ mol/l (A) and 8.1 μ mol/l (B) for human and rat, respectively, were taken as 100% activity.

Fig. 3. Inhibitory effects of AK106-001616 on the release of AA, PGE₂, and LTB₄. (A) AA release from Ca²⁺ ionophore A23187-stimulated RBL-2H3 cells. Radioactivity of released tritium labeled AA in the absence of AK106-001616 was 1410 dpm. (B) PGE₂ release from LPS-stimulated human PBMCs. Released PGE₂ in the absence of AK106-001616 was 4322 pg/ml. (C) LTB₄ release from A23187-stimulated RBL-2H3 cells. Each value represents the mean $\pm$ S.D. of three data points. Released LTB₄ in the absence of AK106-001616 was 1491 pg/ml.

the evaluation, the method of statistical analysis and its sequential procedure, and the sample size were determined before the start of the test.

The sequential procedure is described subsequently. However, if pathology preparation or positive target drug was not included, the corresponding analysis was skipped.

Step 1: When the value of the disease group has changed significantly compared with the value of the intact group, the value before pathogenesis preparation, or the value of solvent used for pathogenesis preparation, the following analysis is carried out. (If not, do not analyze steps 2 and 3).

Fig. 4. Effects on PGE₂ (A) and LTB₄ (B) production in an in vivo model. Compounds were administered orally at the indicated dose 1 hour before zymosan injection in the air pouch on the back of the rat. PGE₂ and LTB₄ production in the air pouch was measured 3 hours after zymosan stimulation. In the control group, only air was injected without zymosan injection. Each value represents the mean $\pm$ S.E.M. of 10 animals. Significant differences: ** P < 0.005 by the Williams test compared with the vehicle group; \$\$ P < 0.01 by the t test compared with the control group; ## P < 0.01 by the t test compared with the vehicle group.

Step 2: If a significant effect of a positive control drug is observed, perform the following analysis. (If not, do not analyze step 3).

Step 3: Perform statistical analysis at the endpoint.

For comparison between the two groups, the parametric *t* test or nonparametric Wilcoxon method was used. The parametric Williams or nonparametric Shirley-Williams test was used for comparison of multiple groups where dose response was assumed based on preliminary test results. The parametric Dunnett or nonparametric Steel test was used for comparison of other multiple groups. Significant differences were determined using the *t*, Williams, Dunnett, Wilcoxon, and Steel tests using SAS version 8.2 or 9.2 (SAS Institute Inc., Cary, NC) and EXSUS version 7.7.1 (CAC EXICARE, Tokyo, Japan). Differences were considered significant when $P < 0.025$ (using the Williams test) or $P < 0.05$ (using other tests).

Results

In Vitro Enzyme Studies. AK106-001616 inhibited human cPLA₂ enzyme activity in a concentration-dependent manner with an IC₅₀ value of 3.8 nmol/l (Fig. 2A). AK106-001616 also inhibited rat cPLA₂ with an IC₅₀ value of 4.3 nmol/l (Fig. 2B), which is the IC₅₀ value almost identical to that of human cPLA₂. In contrast, the inhibitory activity of AK106-001616 for human iPLA₂ was approximately 15,000 times weaker (IC₅₀ = 55.1 μmol/l) than that of cPLA₂. The inhibitory activity of AK106-001616 on bovine sPLA₂ IB was approximately 26,000 or more times weaker (IC₅₀ > 100 μmol/l) than that of human cPLA₂. AK106-001616 did not affect the activity of PAF-acetylhydrolase (also known as type VII PLA₂) at concentrations of up to 500 μmol/l.

Cellular Studies. AK106-001616 suppressed the release of AA from Ca²⁺ ionophore A23187-stimulated rat RBL-2H3 cells with an IC₅₀ value of 5.5 nmol/l (Fig. 3A). AK106-001616 also suppressed the production of PGE₂ by LPS-stimulated human PBMCs, with an IC₅₀ value of 5.1 nmol/l (Fig. 3B), and the production of LTB₄ by Ca²⁺ ionophore A23187-stimulated RBL-2H3 cells, with an IC₅₀ value of 2.6 nmol/l (Fig. 3C). These IC₅₀ values are consistent with the value of cPLA₂ enzyme inhibition reported previously.

In Vivo Air Pouch Model. Suppression of PGE₂ and LTB₄ production was also observed in an in vivo animal model. Zymosan-induced production of PGE₂ and LTB₄ in the air pouch on the back of the rat was reduced when AK106-001616 was administered orally, compared with vehicle treatment ($P < 0.005$ at 1 or 0.3 mg/kg or more, respectively, by Williams test). The suppressive effects of AK106-001616 on the production of PGE₂ and LTB₄ in this animal study were found to be dose dependent (Fig. 4), and ED₅₀ values of 1.28 and 0.34 mg/kg, respectively, were observed. In this model, oral administration of celecoxib 1 mg/kg decreased PGE₂ production ($P < 0.01$ by *t* test) but increased LTB₄ production ($P < 0.01$ by *t* test) compared with the vehicle group (Fig. 4). Zileuton, a 5-LOX inhibitor, suppressed the production of LTB₄ ($P < 0.01$ by *t* test) without altering the production of PGE₂ ($P > 0.05$ by *t* test) (Fig. 4).

Effect on Arthritis Models. Contralateral paw swelling developed over time in a rat AIA model (data not shown). Repeated administration of AK106-001616 or naproxen starting at day 13 showed dose-dependent inhibition of contralateral paw swelling in the AIA model ($P < 0.005$ at 1 or 0.3 mg/kg or more, respectively, by Williams test) (Fig. 5A). Zileuton did

Fig. 5. Inhibitory effects on swelling in the rat AIA (A) and mouse CAIA (B) models. (A) Compounds were administered orally at the indicated dose once a day from day 13 to 34 after adjuvant injection. Swelling volumes of contralateral foot pads were measured at day 34. Each value represents the mean $\pm$ S.E.M. of six animals. Control: intact group. Significant differences: ** $P < 0.005$ by the Shirley-Williams test compared with the vehicle group; ** $P < 0.01$ by the Wilcoxon test compared with the control group; ## $P < 0.005$; # $P < 0.025$ by the Shirley-Williams test compared with the vehicle group. (B) The mouse CAIA model was made by the injection of anti-type II collagen antibody on day 0 and LPS on day 3. Compounds were administered orally at the indicated dose twice a day from day 0 to 10. Cumulative swelling scores of the four limbs were assessed on day 10. Each circle plot and X represents an individual score and median, respectively. Control: intact group. Significant differences: ** $P < 0.01$ by the Steel test compared with the vehicle group; ** $P < 0.01$ by the Wilcoxon test compared with the control group.

not inhibit paw swelling even when 30 mg/kg was administered in the rat AIA model ($P > 0.05$ vs. vehicle group by *t* test) (Fig. 5A). In another experiment of the rat AIA model, the urinary LTE₄ of the zileuton group (1.4 ± 0.1 pg/μg creatinine, $n = 5$) at days 17 to 18 was significantly lower than that of the vehicle group (4.5 ± 0.2 pg/μg creatinine, $n = 5$; $P < 0.01$ by *t* test), but there was no difference in the PGEM level between the zileuton group (4.4 ± 0.3 pg/μg creatinine, $n = 5$)

and the vehicle group (4.6 ± 0.3 pg/ μ g creatinine, $n = 5$; $P > 0.05$ by t test).

In a mouse CAIA model, AK106-001616 or zileuton significantly suppressed cumulative swelling score for the limbs at a dose of 30 mg/kg compared with the vehicle group ($P < 0.01$ by Steel test) (Fig. 5B). Meanwhile, in this model, naproxen did not significantly suppress swelling of the limbs compared with vehicle treatment ($P > 0.05$ by Steel test) (Fig. 5B). In another experiment of the mouse CAIA model, the urinary LTE₄ of the zileuton group (1.6 ± 0.3 pg/ μ g creatinine, $n = 4$) at days 3 to 4 was significantly lower than that of the vehicle group (6.4 ± 0.3 pg/ μ g creatinine, $n = 4$; $P < 0.01$ by t test), but there was no difference in the PGEM level between the zileuton group (2.7 ± 0.2 pg/ μ g creatinine, $n = 4$) and the vehicle group (2.7 ± 0.2 pg/ μ g creatinine, $n = 5$; $P > 0.05$ by t test).

Analgesic Effects in a Rat Carrageenan-Induced Inflammatory Pain Model. As shown in Fig. 6A, carrageenan induced mechanical hyperalgesia, as demonstrated by a decrease in the paw withdrawal threshold. AK106-001616 administered on a single occasion dose dependently reversed the decrease in the paw withdrawal threshold in carrageenan-induced hyperalgesia compared with vehicle treatment ($P < 0.005$ at 3 and 30 mg/kg by the Williams test) (Fig. 6A). Naproxen also improved the paw threshold reduction in a dose-dependent manner compared with vehicle treatment ($P < 0.005$ at 3 and 30 mg/kg by the Williams test) (Fig. 6B). Celecoxib reversed the decrease in threshold induced by carrageenan at a dose of 3 mg/kg ($P < 0.01$ by t test compared with the vehicle group) (Fig. 6A).

Analgesic Effects in a Rat CCI-Induced Neuropathic Pain Model. As shown in Fig. 7, mechanical hyperalgesia, a decrease in the paw withdrawal threshold, developed over time on the ipsilateral hind paw in CCI model rats. The threshold of the vehicle group on day 14 was confirmed to be significantly lower than that of the vehicle group 1 day before CCI surgery ($P < 0.01$ by t test). Repeated administration once daily for 7 days from day 8 of AK106-001616 dose dependently reversed the decrease in the paw withdrawal threshold in CCI rats, and its effect was significant at 3 mg/kg or more on day 14 ($P < 0.005$ by the Williams test compared with the vehicle group) (Fig. 7A). However, repeated administration of effective doses of naproxen or celecoxib in the carrageenan model did not recover the paw withdrawal threshold on day 14 in CCI rats ($P > 0.025$ by the Williams test compared with the vehicle group) (Fig. 7B).

Effects on Bleomycin-Induced Lung Fibrosis in Mice. Intratracheal injection of bleomycin induced a significant increase in the Ashcroft score of lung fibrosis in all mice ($P < 0.01$ by the Wilcoxon test compared with the control group) (Fig. 8). Nintedanib significantly reduced the Ashcroft score compared with the vehicle group ($P < 0.01$ by the Wilcoxon test) (Fig. 8). AK106-001616 at 30 mg/kg significantly reduced the Ashcroft score in mice ($P < 0.05$ by the Steel test compared with the vehicle group), but dose dependency was not confirmed (Fig. 8).

Effects of Single Dosing on Aspirin-Induced Gastric Damage in Rats. Aspirin alone produced marked macroscopic gastric damage in all 12 individuals (Fig. 9). Co-administration of celecoxib and aspirin produced a significant increase

Fig. 6. (A and B) Analgesic effects in a rat carrageenan-induced inflammatory pain model. Compounds were administered orally at the indicated dose 1 hour before carrageenan injection into a hind paw. Paw withdrawal thresholds were measured before dosing and 4 hours after carrageenan injection using the Randall-Selitto method. Each value represents the mean $\pm$ S.E.M. of 10 animals. Significant differences: ** $P < 0.005$ by the Williams test compared with the vehicle group; \$\$ $P < 0.01$ by the t test compared with the prevalues in the vehicle group; ## $P < 0.01$ by the t test compared with the vehicle group.

Fig. 7. (A and B) Analgesic effects in a rat neuropathic pain model induced by sciatic nerve CCI. Fifty-six CCI rats were prepared, and 50 animals were selected on day 7 and divided into five groups ($n = 10/\text{group}$). Compounds were administered orally at the indicated dose once a day from day 8 to 14 after surgery. Paw withdrawal thresholds were measured using the Randall-Selitto method. Each value represents the mean $\pm$ S.E.M. Statistical testing was performed at day 14. Significant differences: $**P < 0.005$ by the Williams test compared with the vehicle group; $^{**}P < 0.01$ by the t test compared with the prevalues in the vehicle group. There were no significant differences in the celecoxib and naproxen groups compared with the vehicle group; $P > 0.05$ by the Dunnett test.

in the mean lesion score compared with aspirin alone ($P < 0.01$ by t test) (Fig. 9). Coadministration of AK106-001616 and aspirin did not produce a significant increase in the mean lesion score compared with aspirin alone ($P > 0.05$ by the Dunnett test) (Fig. 9).

Effects of Repeated Dosing on Blood Pressure in Rats. The systolic blood pressure of the vehicle-treated group increased with time (Fig. 10A). Repeated administration of rofecoxib produced a significant increase in systolic blood pressure on day 28 of dosing compared with the vehicle control group ($P < 0.01$ by the t test) (Fig. 10A). Repeated administration of AK106-001616 did not produce a significant increase

Fig. 8. Effects on bleomycin-induced lung fibrosis in mice. AK106-001616 and nintedanib were administered orally twice and once a day, respectively, from day 7 to 21 after intratracheal bleomycin administration. (A) Representative photomicrographs of Masson's trichrome-stained lung sections. (B) Ashcroft score. Each circle plot and X represents an individual score and median ($n = 7-12$), respectively. Control: intact group. Significant differences: $*P < 0.05$ by the Steel test compared with the vehicle group; $^{**}P < 0.01$ by the Wilcoxon test compared with the control group; $^{**}P < 0.01$ by the Wilcoxon test compared with the vehicle group.

in systolic blood pressure ($P > 0.05$ by the Dunnett test compared with the vehicle group) (Fig. 10A).

Effects on LPS-Induced Production of TXA₂ and PGI₂ in the Rat. Rofecoxib suppressed the production of 6-keto PGF_{1 α} dose dependently, with significant suppression at 3 and 30 mg/kg ($P < 0.005$ by the Williams test compared with the vehicle group) (Fig. 10B). On the other hand, rofecoxib did not produce any significant change in the plasma level of TXB₂ ($P > 0.05$ by the Dunnett test compared with the vehicle group) (Fig. 10C). The ratios of the TXB₂ level to the 6-keto

Fig. 9. Effects of single dosing on aspirin-induced gastric damage in rats. A mixture of aspirin and either AK106-001616 or celecoxib was administered as a single oral dose 6 hours before assessment of the gastric lesion score (sum of the lengths of damage of the mucosa). Each value represents the mean $\pm$ S.E.M. of 12 animals. Significant differences: ## P < 0.01 by the t test compared with the vehicle group. There were no significant differences in AK106-001616 groups compared with the vehicle group; P > 0.05 by the Dunnett test.

PGF_{1 α} level were significantly higher in the rofecoxib groups (3 and 30 mg/kg) than in the vehicle-treated group (P < 0.01 by the Dunnett test) (Fig. 10D). AK106-001616 produced a significant decrease at 3 and 30 mg/kg in the levels of both TXB₂ and 6-keto PGF_{1 α} (P < 0.005 by the Williams test compared with the vehicle group) (Fig. 10, B and C), but it did not increase the ratio of TXB₂ to 6-keto PGF_{1 α} (P > 0.05 by the Dunnett test) (Fig. 10D).

Discussion

AK106-001616 specifically inhibited cPLA₂, and no difference between humans and rats was observed in its enzyme inhibitory activity. In cell-based assays, AK106-001616 inhibited the secretion of AA and the production of PGs and LTs to the same extent, and its inhibitory concentration was consistent with the enzyme inhibitory activity. AK106-001616 suppressed the production of PGs and LTs to the same extent in the in vivo test. From the results in the rat AIA model, the dose of AK106-001616 was 0.3–30 mg/kg, with associated plasma free concentrations ($C_{\max}$) of 79–3040 nmol/l (Table 1). This in vivo concentration range was included in the concentration range specifically inhibiting the activity of cPLA₂ (Fig. 2). In a clinical phase IIa trial multicenter study with a randomized and double-blind design, AK106-001616 (100 mg twice daily over a 28-day treatment period) inhibited the production of PGs and LTs, and was efficacious and well tolerated by patients with RA (Yamanishi et al., 2013). These results confirmed the concept that AK106-001616 reduces PGs and LTs by inhibiting cPLA₂.

cPLA₂ is the first regulatory enzyme that releases AA, which is a precursor for diverse bioactive lipid metabolites that can have opposing effects. Therefore, it is possible that AK106-001616 suppresses the production of not only inflammatory mediators but also anti-inflammatory mediators. In this study, since AK106-001616 eventually suppressed inflammation of

Fig. 10. (A) Effects on systolic blood pressure in rats. Compounds were administered orally at the indicated dose once a day for 28 days. Each value represents the mean $\pm$ S.E.M. of 10 animals. Statistical testing was performed at day 28. Significant differences: ## P < 0.01 by the t test compared with the vehicle group. There were no significant differences in the AK106-001616 groups compared with the vehicle group; P > 0.05 by the Dunnett test (B). (C) Inhibition of LPS-induced production of PGI₂ and TXA₂ in rats. Compounds were administered orally at the indicated dose 1 hour before LPS injection. Plasma levels of 6-keto PGF_{1 α} (B) and TXB₂ (C), which are stable metabolites of PGI₂ and TXA₂, respectively, were measured 1 hour after LPS injection. In the control group, saline was injected without LPS injection. Each value represents the mean $\pm$ S.E.M. of six animals. Significant differences: ** P < 0.005; ## P < 0.005 by the Williams test compared with the vehicle group; §§ P < 0.01 by the t test compared with the control group. (D) The ratios of the TXB₂ level to the 6-keto PGF_{1 α} level. Each value represents the mean $\pm$ S.E.M. of six animals. Significant differences: ## P < 0.01 by the Dunnett test compared with the vehicle group.

TABLE 1

Pharmacokinetic parameters of AK106-001616 based on free plasma concentration after repeated oral administration
Each value represents the mean $\pm$ S.D.

Disease Model	Dose	$C_{\max}$	AUC_{0-24}^a	<i>n</i>
		mg/kg nmol/l	nmol·h/l	
Rat AIA ^b	0.3	79 $\pm$ 88	276 $\pm$ 904	3
	1	82 $\pm$ 16	1010 $\pm$ 360	3
	3	301 $\pm$ 21	3870 $\pm$ 490	3
	10	976 $\pm$ 117	11,800 $\pm$ 2200	3
	30	3040 $\pm$ 660	33,500 $\pm$ 100	3
Mouse CAIA ^c	30	3830 $\pm$ 230	17,100 $\pm$ 1300	3
Rat CCI ^d	0.3	10 $\pm$ 5	808 $\pm$ 263	4
	3	179 $\pm$ 64	1000 $\pm$ 320	4
	30	1340 $\pm$ 260	11,400 $\pm$ 3100	4
	300	3090 $\pm$ 1040	30,800 $\pm$ 14,500	4

^a AUC_{0-24} , area under the curve from 0 to 24 hours.

^b AUC_{0-24} was calculated after repeated administration.

^cAK106-001616 was administered orally again to the animals for collection of blood samples on day 34, which was the next day of the endpoint for inhibitory effects on swelling.

^dAK106-001616 was still administered orally to the animals twice a day until day 12, and then the compound was administered orally again for collection of blood samples on day 13.

^eAK106-001616 was administered orally again to the animals for collection of blood samples on day 15, which was the next day of the endpoint for analgesic effects.

arthritis models, it probably strongly suppressed inflammatory mediators rather than anti-inflammatory mediators.

A mouse CAIA model has been used to show that LTs are required in the pathogenesis of arthritis (Mathis et al., 2007). In the present study, zileuton decreased the urinary levels of LTE₄, which is an indicator of systemic production of LTs, and paw swelling in the CAIA model. Meanwhile, in a rat AIA model, zileuton decreased urinary LTE₄ levels, but did not inhibit paw swelling. These results indicate that LTs contribute to the pathogenesis in the CAIA model, but not in the AIA model. AK106-001616, which inhibits productions of PGs and LTs, suppressed paw swelling in both the AIA and the CAIA models. Naproxen, which suppresses PG production by inhibiting COX, is effective in the AIA model but ineffective in the CAIA model. Since there were no differences in the pharmacokinetic profiles of AK106-001616 and naproxen between the rat AIA and mouse CAIA models (Table 2), the change in the effect of naproxen cannot be accounted for by the difference in the area under the curve between the models. This suggests that PGs contribute to the pathogenesis of the AIA model and but not the CAIA model.

Single oral administration of AK106-001616 inhibited inflammatory pain caused by carrageenan, and its action intensity was equivalent to naproxen and celecoxib. In the CCI

model, effective doses of naproxen and celecoxib in the carrageenan model were ineffective, while AK106-001616 was effective. Since celecoxib did not suppress neuropathic pain despite suppressing PGs, suppression of mediators other than PGs was thought to be involved in the action of AK106-001616 in the neuropathic pain model. It is known that the mediators downstream from cPLA₂, LTs (Noguchi and Okubo, 2011) and PAF (Hasegawa et al., 2010; Okubo et al., 2012; Shindou et al., 2017), are involved in neuropathic pain. This suggests that cPLA₂ inhibitors may have a broader analgesic effect than COX-1 and -2 inhibitors.

The free plasma concentration after administration of 30 mg/kg AK106-001616 in the CCI model was 1340 nmol/l at 2 hours (Table 3). The AK106-001616 level in the cerebrospinal fluid was 500 nmol/l at 2 hours (Table 3). These concentrations were sufficient to inhibit cPLA₂ (Fig. 2). In the peripheral sensory nerve in vivo, the number of cPLA₂-activated neurons was increased after peripheral nerve injury, but not after peripheral inflammation produced by complete Freund's adjuvant (Tsuda et al., 2007). It has also been reported that cPLA₂ is expressed in the spinal cord, predominantly in dorsal horn neurons and oligodendrocytes (Kim et al., 2008). In addition to peripheral inhibition, the central inhibition by AK106-001616 to decrease inflammatory mediators may contribute to mitigate the neuropathic pain seen in CCI rats.

It is well known that downstream mediators of cPLA₂ are involved in the pathology of IPF. LTB₄ (Wilborn et al., 1996), leukotriene C₄ (Wilborn et al., 1996), and prostaglandin F_{2α} (Oga et al., 2009) were elevated in the bronchoalveolar lavage fluid of patients with IPF. In mice overexpressing leukotriene C₄, bleomycin-induced pulmonary fibrosis was more severe than in wild-type mice (Hirata et al., 2013). Knockout of the 5-LO gene (Peters-Golden et al., 2002) and pharmacological inhibition of LTs (Failla et al., 2006) alleviate the pathology in the mouse bleomycin model. Prostaglandin F_{2α} is involved in transforming growth factor β -independent pulmonary fibrosis (Oga et al., 2009). Therefore, AK106-001616, as a cPLA₂ inhibitor, may inhibit pulmonary fibrosis by inhibiting the production of these mediators. Further examination is necessary to prove this hypothesis.

Hypertension is considered one of the risk factors causing CV events. In clinical trials, taking selective COX-2 inhibitors or nonsteroidal anti-inflammatory analgesics caused hypertension (Justice and Carruthers, 2005). COX-2 inhibition increases the vasoconstrictor action and platelet aggregation action of TXA₂ by suppressing PGI₂, which has vasodilating

TABLE 2

Pharmacokinetic parameters after repeated oral administration in the rat AIA and mouse CAIA models

Each value represents the mean $\pm$ S.D.

Drug	Dose	$C_{\max}$		AUC_{0-24}^a	
		Rat AIA Model ^b (<i>n</i> = 3)	Mouse CAIA Model ^c (<i>n</i> = 4)	Rat AIA Model ^b (<i>n</i> = 3)	Mouse CAIA Model ^c (<i>n</i> = 4)
	mg/kg	$\mu\text{mol/l}$	$\mu\text{mol/l}$	$\mu\text{mol·h/l}$	$\mu\text{mol·h/l}$
AK106-001616	30	217 $\pm$ 47	213 $\pm$ 13	2390 $\pm$ 10	949 $\pm$ 71
Naproxen	30	317 $\pm$ 66	280 $\pm$ 21	2123 $\pm$ 436	766 $\pm$ 105
Zileuton	30	54 $\pm$ 2	143 $\pm$ 29	413 $\pm$ 117	281 $\pm$ 42

^a AUC_{0-24} , area under the curve from 0 to 24 hours.

^b AUC_{0-24} was calculated after repeated administration.

^cCompounds were administered orally again to the animals for collection of blood samples on day 34, which was the next day of the endpoint for inhibitory effects on swelling.

^dCompounds were still administered orally to the animals twice a day until day 12, and then the compounds were administered orally again for collection of blood samples on day 13.

TABLE 3

Free plasma and cerebrospinal fluid concentration of AK106-001616 2 h after repeated oral administration at a dose of 30 mg/kg in a rat CCI model

Each value represents the mean $\pm$ S.D. ($n = 3$ to 4).

Concentration	Value
Free plasma concentration (nmol/l)	1340 $\pm$ 259
CSF concentration (nmol/l)	500 $\pm$ 559
K_p (CSF/plasma concentration ratio)	0.37

CSF, cerebrospinal fluid.

and platelet aggregation inhibitory actions; as a result, it increases CV risk (Konstantinopoulos and Lehmann, 2005). In the present study, rofecoxib produced a significant increase in systolic blood pressure in WKY/Hos rats, whereas AK106-001616 did not. In addition, blood pressure is normal in cPLA₂ knockout mice, and hypertension is not induced even when nitric oxide inhibitor or angiotensin II is administered to cPLA₂ knockout mice (Khan et al., 2015). Rofecoxib increased the ratio of TXA₂ to PGI₂, which is thought to be a risk factor in thrombotic CV events (Vainio et al., 2004), whereas AK106-001616 had no effect on this ratio. These results suggest that AK106-001616 does not increase CV risk.

Low-dose aspirin used clinically for CV risk reduction has a risk of causing gastric mucosal disorders. COX-2 inhibitors that do not induce gastric mucosal injury themselves enhance aspirin-induced gastric mucosal injury (Fiorucci et al., 2003). Furthermore, it has been suggested that COX-2 inhibitors increase production of LTB₄ by suppressing other substrates of LOX in aspirin-administered animals (Fiorucci et al., 2003). In the present study, celecoxib enhanced aspirin-induced gastric mucosal injury and increased LTB₄ production. On the other hand, licofelone, a COX/LOX inhibitor, suppressed LTB₄ production and did not exacerbate aspirin-induced gastric mucosal injury (Fiorucci et al., 2003). AK106-001616 also decreased LTB₄ and did not exacerbate aspirin-induced gastric mucosal injury. Therefore, the increase in LTB₄ may be involved in the exacerbation of aspirin-induced gastric mucosal injury. Since this study is a single dose study, it is necessary to further investigate repeated administration of aspirin and AK106-001616.

The GI risk when AK106-001616 was repeatedly administered to RA patients for 28 days was evaluated in the phase IIa trial. The incidence of GI-related treatment-emergent adverse events by AK106-001616 (100 mg twice daily) tended to be less than that of naproxen. AK106-001616 did not change from baseline in the mean number of mucosal breaks without hemorrhage; however, naproxen significantly increased it. These results suggest that AK106-001616 has a better GI profile compared with naproxen.

In this research, there was the limitation of the repeated dose period. The small intestines of the cPLA₂ knockout mice had numerous small ulcers (Takaku et al., 2000). Several patients with inherited cPLA₂ deficiency had abnormalities in the GI tract (Leslie, 2015), and catastrophic GI disease was also included (Brooke et al., 2014). Furthermore, long-term inhibition of cPLA₂ in chronic dosing may have a serious effect on membrane remodeling. Therefore, in the future, risks due to chronic administration of AK106-001616 should be evaluated and an appropriate administration period should be found.

In summary, AK106-001616 is a potent and orally available inhibitor of cPLA₂. In rodents, AK106-001616 inhibited inflammation, inflammatory and neuropathic pain, and pulmonary fibrosis. On the other hand, AK106-001616 did not enhance aspirin-induced gastric damage and did not increase blood pressure and the TXA₂/PGI₂ ratio. The present data demonstrate that AK106-001616 may provide valuable effects in a wide range of indications without the attendant GI and CV risks.

Authorship Contributions

Participated in research design: Shimizu, Nakamura, Ito, Kuriyama.
Conducted experiments: Nakamura, Shimizu, Ito, Sakurada, Tanaka, Komatsu, Takeda, Endo, Saito, Kozaki.
Contributed new reagents or analytic tools: Shoda.
Performed data analysis: Shimizu, Nakamura, Ito.
Wrote or contributed to the writing of the manuscript: Ito, Shimizu.

References

- Allen A, Carville S, and McKenna F; Guideline Development Group (2018) Diagnosis and management of rheumatoid arthritis in adults: summary of updated NICE guidance. *BMJ* **362**:k3015.
- Anderson GD, Keys KL, De Ciechi PA, and Masferrer JL (2009) Combination therapies that inhibit cyclooxygenase-2 and leukotriene synthesis prevent disease in murine collagen induced arthritis. *Inflamm Res* **58**:109–117.
- Ashcroft T, Simpson JM, and Timbrell V (1988) Simple method of estimating severity of pulmonary fibrosis on a numerical scale. *J Clin Pathol* **41**:467–470.
- Baba H (1988) [Experimental study on the pathophysiology of endotoxin shock as analysed by alterations in thromboxane B2 and 6-keto-PGF1 alpha levels]. *Nihon Geka Gakkai Zasshi* **89**:6–20.
- Binder A and Baron R (2016) The pharmacological therapy of chronic neuropathic pain. *Dtsch Arztebl Int* **113**:616–625.
- Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K, Lines C, Riddell R, Morton D, Lanas A, et al.; Adenomatous Polyp Prevention on Vioxx (APPROVe) Trial Investigators (2005) Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. *N Engl J Med* **352**:1092–1102.
- Brooke MA, Longhurst HJ, Plagnol V, Kirkby NS, Mitchell JA, Rüschendorf F, Warner TD, Kelsell DP, and MacDonald TT (2014) Cryptogenic multifocal ulcerating stenosing enteritis associated with homozygous deletion mutations in cytosolic phospholipase A2- α . *Gut* **63**:96–104.
- Combe B, Landewe R, Lukas C, Bolosiu HD, Breedveld F, Dougados M, Emery P, Ferraccioli G, Hazes JM, Klareskog L, et al. (2007) EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). *Ann Rheum Dis* **66**:34–45.
- Cortes-Burgos LA, Zweifel BS, Settle SL, Pufahl RA, Anderson GD, Hardy MM, Weir DE, Hu G, Happa FA, Stewart Z, et al. (2009) CJ-13610, an orally active inhibitor of 5-lipoxygenase is efficacious in preclinical models of pain. *Eur J Pharmacol* **617**:59–67.
- de Carvalho MS, McCormack FX, and Leslie CC (1993) The 85-kDa, arachidonic acid-specific phospholipase A₂ is expressed as an activated phosphoprotein in Sf9 cells. *Arch Biochem Biophys* **306**:534–540.
- Failla M, Genovese T, Mazzon E, Gili E, Muià C, Sortino M, Crimi N, Caputi AP, Cuzzocrea S, and Vancheri C (2006) Pharmacological inhibition of leukotrienes in an animal model of bleomycin-induced acute lung injury. *Respir Res* **7**:137.
- Farkouh ME and Greenberg BP (2009) An evidence-based review of the cardiovascular risks of nonsteroidal anti-inflammatory drugs. *Am J Cardiol* **103**:1227–1237.
- Fiorucci S, Distrutti E, de Lima OM, Romano M, Mencarelli A, Barbanti M, Palazzini E, Morelli A, and Wallace JL (2003) Relative contribution of acetylated cyclooxygenase (COX)-2 and 5-lipoxygenase (LOX) in regulating gastric mucosal integrity and adaptation to aspirin. *FASEB J* **17**:1171–1173.
- Ghosh M, Tucker DE, Burchett SA, and Leslie CC (2006) Properties of the Group IV phospholipase A₂ family. *Prog Lipid Res* **45**:487–510.
- Glover S, de Carvalho MS, Bayburt T, Jonas M, Chi E, Leslie CC, and Gelb MH (1995) Translocation of the 85-kDa phospholipase A₂ from cytosol to the nuclear envelope in rat basophilic leukemia cells stimulated with calcium ionophore or IgE/antigen. *J Biol Chem* **270**:15359–15367.
- Hagmann W (1994) Cell proliferation status, cytokine action and protein tyrosine phosphorylation modulate leukotriene biosynthesis in a basophil leukaemia and a mastocytoma cell line. *Biochem J* **299**:467–472.
- Hasegawa S, Kohro Y, Shiratori M, Ishii S, Shimizu T, Tsuda M, and Inoue K (2010) Role of PAF receptor in proinflammatory cytokine expression in the dorsal root ganglion and tactile allodynia in a rodent model of neuropathic pain. *PLoS One* **5**:e10467.
- Hegen M, Sun L, Uozumi N, Kume K, Goad ME, Nickerson-Nutter CL, Shimizu T, and Clark JD (2003) Cytosolic phospholipase A₂-deficient mice are resistant to collagen-induced arthritis. *J Exp Med* **197**:1297–1302.
- Hirata H, Arima M, Fukushima Y, Sugiyama K, Tokuhisa T, and Fukuda T (2013) Leukotriene C₄ aggravates bleomycin-induced pulmonary fibrosis in mice. *Respirology* **18**:674–681.
- Hochberg MC, Altman RD, April KT, Benkhalti M, Guyatt G, McGowan J, Towheed T, Welch V, Wells G, and Tugwell P; American College of Rheumatology (2012) American College of Rheumatology 2012 recommendations for the use of

- nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. *Arthritis Care Res (Hoboken)* **64**:465–474.
- Höcherl K, Endemann D, Kammerl MC, Grobecker HF, and Kurtz A (2002) Cyclooxygenase-2 inhibition increases blood pressure in rats. *Br J Pharmacol* **136**:1117–1126.
- Hutamekalin P, Saito T, Yamaki K, Mizutani N, Brand DD, Waritani T, Terato K, and Yoshino S (2009) Collagen antibody-induced arthritis in mice: development of a new arthritogenic 5-clone cocktail of monoclonal anti-type II collagen antibodies. *J Immunol Methods* **343**:49–55.
- Ito A, Takeda M, Yoshimura T, Komatsu T, Ohno T, Kuriyama H, Matsuda A, and Yoshimura M (2012) Anti-hyperalgesic effects of calcitonin on neuropathic pain interacting with its peripheral receptors. *Mol Pain* **8**:42.
- Jain NK, Kulkarni SK, and Singh A (2001) Role of cysteinyl leukotrienes in nociceptive and inflammatory conditions in experimental animals. *Eur J Pharmacol* **423**:85–92.
- Jenkins CM, Han X, Mancuso DJ, and Gross RW (2002) Identification of calcium-independent phospholipase A₂ (iPLA₂) β , and not iPLA₂ γ , as the mediator of arginine vasopressin-induced arachidonic acid release in A-10 smooth muscle cells. Enantioselective mechanism-based discrimination of mammalian iPLA₂s. *J Biol Chem* **277**:32807–32814.
- Justice E and Carruthers DM (2005) Cardiovascular risk and COX-2 inhibition in rheumatological practice. *J Hum Hypertens* **19**:1–5.
- Khan NS, Song CY, Jennings BL, Estes AM, Fang XR, Bonventre JV, and Malik KU (2015) Cytosolic phospholipase A₂ is critical for angiotensin II-induced hypertension and associated cardiovascular pathophysiology. *Hypertension* **65**:784–792.
- Kim DH, Fitzsimmons B, Hefferan MP, Svensson CI, Wanciewicz E, Monia BP, Hung G, Butler M, Marsala M, Hua XY, et al. (2008) Inhibition of spinal cytosolic phospholipase A₂ expression by an antisense oligonucleotide attenuates tissue injury-induced hyperalgesia. *Neuroscience* **154**:1077–1087.
- Konstantinopoulos PA and Lehmann DF (2005) The cardiovascular toxicity of selective and nonselective cyclooxygenase inhibitors: comparisons, contrasts, and aspirin confounding. *J Clin Pharmacol* **45**:742–750.
- Kudo I and Murakami M (2002) Phospholipase A₂ enzymes. *Prostaglandins Other Lipid Mediat* **68–69**:3–58.
- Larsson PK, Claesson HE, and Kennedy BP (1998) Multiple splice variants of the human calcium-independent phospholipase A₂ and their effect on enzyme activity. *J Biol Chem* **273**:207–214.
- Laufer S (2003) Role of eicosanoids in structural degradation in osteoarthritis. *Curr Opin Rheumatol* **15**:623–627.
- Leslie CC (2015) Cytosolic phospholipase A₂: physiological function and role in disease. *J Lipid Res* **56**:1386–1402.
- Leslie CC and Gelb MH (2004) Assaying phospholipase A₂ activity. *Methods Mol Biol* **284**:229–242.
- Liu YM, Nepali K, and Liou JP (2017) Idiopathic pulmonary fibrosis: current status, recent progress, and emerging targets. *J Med Chem* **60**:527–553.
- Maiorini-Dullin L, Boussac-Marlière N, Geffray B, Hameiz C, Hitier S, and Onado V (2007) On the efficiency of interim analyses applied to nonclinical studies. *Drug Inf J* **41**:517–526.
- Masferrer JL, Zweifel BS, Hardy M, Anderson GD, Dufield D, Cortes-Burgos L, Pufahl RA, and Graneto M (2010) Pharmacology of PF-4191834, a novel, selective non- α -5-lipoxygenase inhibitor effective in inflammation and pain. *J Pharmacol Exp Ther* **334**:294–301.
- Mathis S, Jala VR, and Haribabu B (2007) Role of leukotriene B₄ receptors in rheumatoid arthritis. *Autoimmun Rev* **7**:12–17.
- Nagase T, Uozumi N, Ishii S, Kita Y, Yamamoto H, Ohga E, Ouchi Y, and Shimizu T (2002) A pivotal role of cytosolic phospholipase A₂ in bleomycin-induced pulmonary fibrosis. *Nat Med* **8**:480–484.
- National Clinical Guideline Centre (2014) Osteoarthritis: care and management in adults, National Clinical Guideline Centre, London.
- Noguchi K and Okubo M (2011) Leukotrienes in nociceptive pathway and neuropathic/inflammatory pain. *Biol Pharm Bull* **34**:1163–1169.
- Nussmeier NA, Whelton AA, Brown MT, Langford RM, Hoeft A, Parlow JL, Boyce SW, and Verburg KM (2005) Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. *N Engl J Med* **352**:1081–1091.
- Oga T, Matsuoka T, Yao C, Nonomura K, Kitaoka S, Sakata D, Kita Y, Tanizawa K, Taguchi Y, Chin K, et al. (2009) Prostaglandin F_{2a} receptor signaling facilitates bleomycin-induced pulmonary fibrosis independently of transforming growth factor- β . *Nat Med* **15**:1426–1430.
- Okubo M, Yamanaka H, Kobayashi K, Kanda H, Dai Y, and Noguchi K (2012) Up-regulation of platelet-activating factor synthases and its receptor in spinal cord contribute to development of neuropathic pain following peripheral nerve injury. *Mol Pain* **8**:8.
- OWada Y, Tominaga T, Yoshimoto T, and Kondo H (1994) Molecular cloning of rat cDNA for cytosolic phospholipase A₂ and the increased gene expression in the dentate gyrus following transient forebrain ischemia. *Brain Res Mol Brain Res* **25**:364–368.
- Payá M, García Pastor P, Coloma J, and Alcaraz MJ (1997) Nitric oxide synthase and cyclo-oxygenase pathways in the inflammatory response induced by zymosan in the rat air pouch. *Br J Pharmacol* **120**:1445–1452.
- Payá M, Terencio MC, Ferrández ML, and Alcaraz MJ (1996) Involvement of secretory phospholipase A₂ activity in the zymosan rat air pouch model of inflammation. *Br J Pharmacol* **117**:1773–1779.
- Peters-Golden M, Baillie M, Marshall T, Wilke C, Phan SH, Toews GB, and Moore BB (2002) Protection from pulmonary fibrosis in leukotriene-deficient mice. *Am J Respir Crit Care Med* **165**:229–235.
- Prete PE and Gurakar-Osborne A (1997) The contribution of synovial fluid lipoproteins to the chronic synovitis of rheumatoid arthritis. *Prostaglandins* **54**:689–698.
- Raghu G, Rochwerf B, Zhang Y, Garcia CA, Azuma A, Behr J, Brozek JL, Collard HR, Cunningham W, Homma S, et al.; American Thoracic Society; European Respiratory Society; Japanese Respiratory Society; Latin American Thoracic Association (2015) An official ATS/ERS/JRS/ALAT clinical practice guideline: treatment of idiopathic pulmonary fibrosis. An update of the 2011 clinical practice guideline [published correction appears in *Am J Respir Crit Care Med* (2015) 192:644]. *Am J Respir Crit Care Med* **192**:e3–e19.
- Raichel L, Berger S, Hadad N, Kachko L, Karter M, Szaingurten-Solodkin I, Williams RO, Feldmann M, and Levy R (2008) Reduction of cPLA_{2 α} overexpression: an efficient anti-inflammatory therapy for collagen-induced arthritis. *Eur J Immunol* **38**:2905–2915.
- Sharp JD, White DL, Chiou XG, Goodson T, Gamboa GC, McClure D, Burgett S, Hoskins J, Skatrud PL, Sportsman JR, et al. (1991) Molecular cloning and expression of human Ca²⁺-sensitive cytosolic phospholipase A₂. *J Biol Chem* **266**:14850–14853.
- Shindou H, Shiraishi S, Tokuoka SM, Takahashi Y, Harayama T, Abe T, Bando K, Miyano K, Kita Y, Uezono Y, et al. (2017) Relief from neuropathic pain by blocking of the platelet-activating factor-pain loop. *FASEB J* **31**:2973–2980.
- Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Finn P, Anderson WF, Zaubler A, Hawk E, and Bertagnoli M; Adenoma Prevention with Celecoxib (APC) Study Investigators (2005) Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. *N Engl J Med* **352**:1071–1080.
- Stafforini DM, Prescott SM, and McIntyre TM (1987) Human plasma platelet-activating factor acetylhydrolase. Purification and properties. *J Biol Chem* **262**:4223–4230.
- Sung B, Wang S, Zhou B, Lim G, Yang L, Zeng Q, Lim JA, Wang JD, Kang JX, and Mao J (2007) Altered spinal arachidonic acid turnover after peripheral nerve injury regulates regional glutamate concentration and neuropathic pain behaviors in rats. *Pain* **131**:121–131.
- Tai N, Kuwabara K, Kobayashi M, Yamada K, Ono T, Seno K, Gahara Y, Ishizaki J, and Hori Y (2010) Cytosolic phospholipase A₂ α inhibitor, pyrroxyphenol, displays anti-arthritis and anti-bone destructive action in a murine arthritis model. *Inflamm Res* **59**:53–62.
- Takaku K, Sonoshita M, Sasaki N, Uozumi N, Doi Y, Shimizu T, and Taketo MM (2000) Suppression of intestinal polyposis in Apc⁷¹⁶ knockout mice by an additional mutation in the cytosolic phospholipase A₂ gene. *J Biol Chem* **275**:34013–34016.
- Tanahashi M, Funaba Y, Itoh M, Kawabe N, and Nakadate-Matsushita T (1998) Inhibitory effects of TRK-530 on rat adjuvant arthritis. *Pharmacology* **56**:242–251.
- Tojo H, Ono T, and Okamoto M (1993) Reverse-phase high-performance liquid chromatographic assay of phospholipases: application of spectrophotometric detection to rat phospholipase A₂ isozymes. *J Lipid Res* **34**:837–844.
- Trelle S, Reichenbach S, Wandel S, Hildebrand P, Tschannen B, Villiger PM, Egger M, and Jüni P (2011) Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. *BMJ* **342**:c7086.
- Tsuda M, Hasegawa S, and Inoue K (2007) P2X receptors-mediated cytosolic phospholipase A₂ activation in primary afferent sensory neurons contributes to neuropathic pain. *J Neurochem* **103**:1408–1416.
- Vainio M, Riutta A, Koivisto AM, and Mäenpää J (2004) Prostacyclin, thromboxane A₂ and the effect of low-dose ASA in pregnancies at high risk for hypertensive disorders. *Acta Obstet Gynecol Scand* **83**:1119–1123.
- Wakitani K, Nanayama T, Masaki M, and Matsushita M (1998) Profile of JTE-522 as a human cyclooxygenase-2 inhibitor. *Jpn J Pharmacol* **78**:365–371.
- Wilborn J, Baillie M, Coffey M, Burdick M, Strieter R, and Peters-Golden M (1996) Constitutive activation of 5-lipoxygenase in the lungs of patients with idiopathic pulmonary fibrosis. *J Clin Invest* **97**:1827–1836.
- Wolf MJ and Gross RW (1996) Expression, purification, and kinetic characterization of a recombinant 80-kDa intracellular calcium-independent phospholipase A₂. *J Biol Chem* **271**:30879–30885.
- Yamanishi K, Ellis B, Kudo K, Kayanoki T, Dews I, Ostor A, and Wilson A (2013) The novel cPLA₂ inhibitor AK106-001616 is a new category of antiinflammatory/analgesic drug demonstrating efficacy and favorable tolerability in the treatment of rheumatoid arthritis. *Ann Rheum Dis* **72** (Suppl 3):240.
- Yamashita M, Kushiara M, Hirasawa N, Takasaki W, Takahagi H, Takayanagi M, and Ohuchi K (2000) Inhibition by troglitazone of the antigen-induced production of leukotrienes in immunoglobulin E-sensitized RBL-2H3 cells. *Br J Pharmacol* **129**:367–373.
- Yoo S, Han S, Park YS, Lee JH, Oh U, and Hwang SW (2009) Lipoxygenase inhibitors suppressed carrageenan-induced Fos-expression and inflammatory pain responses in the rat. *Mol Cells* **27**:417–422.
- Yoshino T, Kimoto A, Kobayashi S, Noguchi M, Fukunaga M, Hayashi A, Miyata K, and Sasamata M (2005) Pharmacological profile of celecoxib, a specific cyclooxygenase-2 inhibitor. *Arzneimittelforschung* **55**:394–402.

Address correspondence to: Akitoshi Ito, Laboratory for Pharmacology, Pharmaceuticals Research Center, Asahi Kasei Pharma Co. Ltd., 632-1 Mifuku, Izunokuni, Shizuoka 410-2321, Japan. E-mail: ito.ab@om.asahi-kasei.co.jp